Whalesbook
Natco Pharma's stock fell over 2% after receiving seven observations from the US Food and Drug Administration (USFDA) following an inspection at its Manali, Chennai API Unit. The company reported a 23.44% decline in consolidated net profit for Q2 FY2025 to ₹517.9 crore, impacted by higher R&D expenses and a one-time employee bonus. The stock has fallen 38% year-to-date.